phamide (60 mg/kg once daily, i.v. on days 1 and 2, total isothiocyanate-conjugated anti-murine IgG antibody for CD68 (dilution 1/20). dose 120 mg/kg) and total body irradiation (12 Gy in 3 days and six fractions). Methotrexate alone was used as GVHD Controls included (1) omission of the first antibody; (2) incubation with isotype-matched irrelevant antibody; (3) prophylaxis. Signs of engraftment were seen by day ϩ20. Abnormal liver function tests appeared on day ϩ143 (total normal liver sections. Histological sections of hepatic specimens from the three patients had common pathologibilirubin = 43 mg/l) and reached a maximum on day ϩ205 (total bilirubin = 260 mg/l). Liver biopsies were taken at cal features. A mild to moderate inflammatory infiltrate was found in all portal tracts ( Figure 1a ). Immunostaining day ϩ147 and day ϩ196 which showed signs of severe acute GVHD. Gut biopsies were also taken at day ϩ194
showed that most of the cells in the portal tract were CD68 positive cells (Figure 1b) , whereas CD3-positive cells were and were in accordance with intestinal GVHD. Death occurred on day ϩ251 from uncontrolled GVHD and rare or absent (Figure 1c) . At higher magnification intraepithelial inflammatory cells were found in the biliary ducts sepsis.
( Figure 2a ) and most were CD68-positive (Figure 2b ), while no intraepithelial inflammatory cells stained with the anti-CD3 antibody (Figure 2c ). On cryostat sections, the Patient 3 double immunolabelings with antibodies directed against CD68 and TNF-alpha showed that most of the cells fluor-A 50-year-old woman was found in January 1993 to have Philadelphia-positive chronic myelogenous leukemia in escent for the anti-CD68 antibody also stained with the anti-TNF-alpha antibody. The CD33-TNF-alpha double chronic phase and received a bone marrow transplant from her HLA-identical brother in September 1993. Conditionimmunolabelings showed comparable results (data not shown). Controls were negative. ing consisted of cyclophosphamide (60 mg/kg once daily, i.v. on days 1 and 2, total dose 120 mg/kg) and busulphan (4 mg/kg p.o in divided doses daily for 4 days, total dose 16 mg/kg). For GVHD prophylaxis, the patient received Discussion methotrexate and cyclosporin A. On day ϩ21, soon after evidence of marrow engraftment (PMN Ͼ500 at day ϩ16) Donor T lymphocytes mediate acute GVHD by direct cytotoxicity or cytokines. 7, 8 The role of TNF-alpha as an effeca macular erythematous rash appeared on the palms of her hands and soles of her feet. Treatment was started with tor of acute GVHD is now well established. Injection of recombinant TNF-alpha into mice induces intestinal and steroids at a dose of 2 mg/kg/day, i.v. but the cutaneous eruption worsened, reaching maximum intensity at day liver necrosis, alveolar damage in the lung, and cachexia. 3 Furthermore, GVHD induces the production of TNF-alpha. ϩ29 with a clinical appearance of toxic epidermal necrosis (TEN). TEN developed despite the use of methylprednisoPassive immunization with anti-TNF IgG reduces GVHDinduced mortality and prevents the weight loss, epidermal lone boli at doses of 20 mg/kg/day, i.v. for 3 days (three sequences of treatment). On day ϩ32, hepatic dysfunction and intestinal alterations and GVHD-induced alveolar damage. 7, 9 In human BMT, increased levels of TNF-alpha have appeared (elevated level of bilirubin). Treatment with antihuman IL-2 receptor monoclonal antibody (LEUKOTAC; been found in the serum of allogeneic BMT recipients and correlated with the severity of GVHD. 10, 11 Biotest) was started on day ϩ36. No improvement of the skin lesions was observed and jaundice appeared at day The cellular origin of TNF-alpha in human GVHD requires definition. Donor T lymphocytes are probably not ϩ42 reaching a maximum on day ϩ46 (Total bilirubin = 70 mg/l). Death from uncontolled GVHD occurred at day the major and direct producers of the cytokines, although their activation could trigger secretion and diffusion of ϩ54. Skin and liver biopsies were taken immediately post-mortem.
large amounts of TNF-alpha with damage to distant organs. 3 T cell lines can produce TNF-alpha in vitro 4 but Biopsies were cut into two parts. One half was immediately fixed in paraformaldehyde 4% in cacodylate buffer, T lymphocytes are low producers of TNF-alpha and their number is low even in severe GVHD within GVHD-affecand further processed for paraffin embedding. The other half was immediately snap-frozen in liquid nitrogen. ted organs. 3 Indeed, GVHD cannot be transferred by lymphoid cells isolated from the organs of affected aniOn consecutive paraffin sections, staining with hematoxylin-eosin, and indirect avidin-biotin immunoperoxidase mals. 3, 12 Another argument is the low frequency of antihost T lymphocytes detected by limiting dilution assay. 13 Alterimmunolabeling with antibodies directed against CD68 (Immunotech, Marseille, France), CD33 (Immunotech), natively, macrophages are also able to secrete high levels of TNF-alpha. 14 In murine GVHD, it is known that macro-CD3 (Immunotech), and TNF-alpha (Genzyme, Cambridge, UK) was performed.
phages are activated as demonstrated by an increase in their phagocytic and bactericidal activity. 15, 16 Recently, macroOn cryostat sections, double immunostaining was secondarily performed with the monoclonal antibody directed phage activity and TNF-alpha production have been investigated in murine GVHD. 17 This study demonstrated that against CD68 and the rabbit polyclonal antibody directed against TNF-alpha. CD33-TNF-alpha double immunostainduring GVHD in mice, macrophages are primed as a result of the allogeneic reaction and produce TNF-alpha. This ing was also performed. After fixation for 15 min in ethanol, cryostat sections were incubated for 60 min with priproduction required priming of macrophages by interferon gamma followed by triggering of production and release by mary antibodies (dilution 1/50). Sections were then incubated for 30 min with a rhodamine-conjugated antilipopolysaccharide (LPS). TNF-alpha production resulted in the symptoms of acute GVHD. Furthermore, macrophage rabbit IgG antibody for TNF-alpha and with a fluorescein Following section treated with an anti-CD3 antibody: no staining of intraepithelial inflammatory cells. Indirect immunoperoxidase ϫ 400.
priming was greater in mice undergoing acute lethal as opposed to non-lethal GVHD.
The most striking feature in these patients was the great preponderance of macrophages in the inflammatory infilThe relevance of the IFN-gamma/macrophage/TNFalpha axis in human acute GVHD remains, however, questrate, observed in all biopsy specimens of all three patients. Our double immunolabeling study demonstrated that most tionable, although an increase in the serum concentration of IFN-gamma also occurs in human BMT before clinical of these macrophages synthesize TNF-alpha (Figure 3a and b). It could be held that CD68 is not entirely specific for manifestations of GVHD. 18 In this study, we chose to focus on three lethal forms of human acute GVHD and a total of macrophages, but lymphocytes were very rare or absent in the infiltrates and we also performed CD33-TNF alpha six biopsy specimens was studied (liver 4, gut 1, skin 1). the patients had been treated for acute GVHD. Pathological features had therefore been modified by the treatments. The macrophagic infiltration observed in our patients might result from a successful lympholytic effect achieved by steroids or other common GVHD treatments. Corticosteroids have a catabolic effect on lymphoid cells and high-dose methylprednisolone can destroy lymphoid cells. Cyclosporin A is a potent immunosuppressive agent blocking activation and proliferation of T lymphocytes through the inhibition of various cytokines. 19, 20 It can particularly block the production of IL-2, IL-3, IL-4, IFN-gamma, and possibly IL-1 mRNA at the nuclear level. 21 The anti-human IL-2 receptor monoclonal antibody LEUKOTAK is designed to control T cell proliferation. None of these treatments targets macrophages. However, it cannot be excluded that primary macrophagic forms of GVHD exist. These forms would logically be unresponsive to usual GVHD treatments which target lymphocytes. Whatever the mechanism, an excessive activation of macrophages resistant to usual GVHD treatments could lead to overproduction of TNF-alpha and lethal GVHD.
Although these results have to be confirmed in a larger series of patients, the role of the macrophage/TNF-alpha axis in human acute GVHD is clear. Its therapeutic implications are potentially high and should be taken into consideration to improve the prognosis of acute GVHD.
